Table 2.

Univariate and multivariate analysis for relapse-free survival (RFS) and overall survival (OS) for patients with stage III melanoma

Univariate Analysis-Stage III
Covariate	RFS			OS
	HR	95%CI	P-value	HR	95%CI	P-value
Age	1.01	1.00–1.03	< 0.03	1.02	1.00–1.03	< 0.02
Sex	1.79	1.13–2.93	< 0.01	1.91	1.14–3.31	< 0.01
Breslow thickness	1.12	1.04–1.19	< 0.004	1.09	1.01–1.18	< 0.03
ALC (continuous)	0.78	0.51–1.17	0.23	0.71	0.45–1.11	0.14
ALC < 2.1 × 109/L	1.29	0.79–2.21	0.31	1.36	0.79–2.50	0.27
AMC (continuous)	1.74	0.67–4.19	0.25	2.82	1.07–6.77	< 0.04
AMC ≥ 0.6 × 109/L	1.57	1.00–2.41	< 0.05	1.89	1.15–3.04	< 0.01
LN ≥ 4	2.32	1.4–3.70	< 0.001	2.56	1.49–4.23	< 0.001
Adjuvant therapy	1.07	0.69–1.63	0.76	0.93	0.58–1.49	0.78
Multivariate Analysis-Stage III
Covariate	RFS			OS
	HR	95%CI	P-value	HR	95%CI	P-value
Age	1.02	0.99–1.03	0.07	1.02	0.99–1.03	0.09
Sex	2.22	1.19–4.44	< 0.01	1.74	0.87–3.79	0.12
Breslow thickness	1.11	1.02–1.19	< 0.02	1.09	0.99–1.18	0.07
AMC ≥ 0.6 × 109/L	1.50	0.87–2.54	0.14	1.79	1.00–3.15	< 0.05
ALC < 2.1 × 109/L	1.10	0.63–2.07	0.74	0.99	0.53–2.01	0.99
LN ≥ 4	1.93	1.03–3.45	< 0.04	2.27	1.15–4.24	< 0.02

Abbreviations: ALC, absolute lymphocyte count; AMC, absolute monocyte count; LN, lymph nodes.